This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D55.2 | V code: V164 | Synonyms: HK deficiency anemia, Hexokinase deficiency, HK deficiency hemolytic anemia, HK1 deficiency
Hemolytic anemia due to hexokinase (HK) deficiency was first reported in 1968 by Valentine and colleagues. This research team was the first to describe markedly reduced red cell hexokinase activity in a patient with chronic non-spherocytic hemolytic anemia in whom the previously known causes (G6PD deficiency, PK deficiency) had been excluded. Sporadic cases were subsequently reported through the 1970s~80s, and HK deficiency became the second glycolytic enzyme deficiency to be discovered, after pyruvate kinase (PK) deficiency. However, unlike PK deficiency, case reports of HK deficiency are extremely rare worldwide, and only fewer than about 100 confirmed cases have been recorded in the literature to date.
In the 1990s, the human hexokinase 1 (HK1) gene was localized to the long arm of chromosome 10 (10q22.1) and cloned. The HK1 gene spans about 100 kb and produces several isoenzymes, including HK-R (the red cell isoform), through tissue-specific splicing. Since the 2000s, with the spread of next-generation sequencing (NGS), HK deficiency cases that had previously gone undiagnosed began to be rediscovered, and as the HK1 gene has been included in red cell disorder diagnostic panels, the diagnostic rate is gradually improving. In Korea, case reports of HK deficiency are very rare, and there are as yet no Korea-specific molecular epidemiological data.
In 1997, Finney and colleagues established a mouse model reproducing HK deficiency (Hk1-deficient mice), and the pathophysiological features of HNSHA confirmed in this model contributed greatly to understanding the mechanism of human HK deficiency. Gene therapy research using animal models (AAV-based HK1 gene delivery) is actively under way, but no clinical-stage therapy has yet been developed.
Hexokinase (HK) is the very first enzyme of glycolysis, catalyzing the reaction that produces glucose-6-phosphate (G6P) and ADP from the substrates glucose and ATP. This reaction is irreversible and serves as the key gateway regulating the entry of glucose into glycolysis. Humans have four HK isoenzymes (HK1~4), of which HK1 is expressed in the brain, muscle, and red blood cells. In red blood cells, HK1 is expressed as a special splice variant called HK-R (erythrocyte-specific isoform), whose protein sequence differs in part from HK1 in other tissues.
When the activity of red cell HK (HK-R) is markedly reduced by pathogenic variants of the HK1 gene, entry of glucose into glycolysis is blocked, and overall red cell energy (ATP) production falls sharply. Because HK is the first enzyme of glycolysis, in HK deficiency all glycolytic intermediates downstream of HK—G6P, fructose-6-phosphate, fructose-1,6-bisphosphate, 3-phosphoglycerate, PEP, and so on—are all decreased. This is a biochemical pattern contrasting with PK deficiency, in which only intermediates upstream of PEP accumulate.
Like PK deficiency, HK deficiency causes HNSHA, but biochemically, because glucose, the substrate of HK, cannot be converted to G6P, glucose influx into the pentose phosphate pathway (PPP) also decreases, so in theory a vulnerability to oxidative stress similar to that of G6PD deficiency may also be present. However, the effect of increased oxidative stress in HK deficiency is reported to be clinically less pronounced than in G6PD deficiency. Clinically, HK deficiency is difficult to distinguish from PK deficiency, so differentiating the two is difficult without accurate enzyme activity measurement or molecular analysis.
The HK1 gene is located on the long arm of chromosome 10 (10q22.1) and spans a genomic region of about 100 kb. HNSHA due to HK deficiency follows an autosomal recessive mode of inheritance. In heterozygous carriers, HK activity is maintained at about 50% of normal and they are clinically healthy, while clinical disease manifests in homozygotes or compound heterozygotes.
The HK1 gene produces several protein isoforms through tissue-specific splicing. The red cell-specific HK-R (Red blood cell isoform) is a form of HK1 with a red cell-specific exon added at the N-terminus, and the protein containing this portion differs from HK1 in other tissues in its binding properties to the red cell membrane. Therefore, variants that specifically affect HK-R can selectively impair only red cell function. Most HK1 pathogenic variants reported to date are missense variants, but splicing variants and large deletions are also reported rarely.
Pathogenic variants causing HK deficiency are not concentrated in particular ethnic groups but occur sporadically in various populations worldwide. Because of this, there are no founder mutations, and complete sequencing of all HK1 exons and splice junctions is needed for diagnosis. In families with confirmed HK deficiency, sibling testing, confirmation of parental carrier status, and, if needed, prenatal molecular diagnosis are performed.
HK deficiency is an extremely rare disease, with only fewer than 100 confirmed cases reported in the literature worldwide. Compared with PK deficiency, at about 1 per 510,000 births, HK deficiency shows a much lower frequency, and no country in the world has an estimate of its exact prevalence. Most reported cases come from Europe, North America, and Japan, and there are no systematic epidemiological data from other regions.
HK deficiency occurs with equal frequency in males and females. Severe homozygous or compound heterozygous patients are often diagnosed with neonatal jaundice or infantile anemia. In patients with a mild carrier-type form or compound heterozygous patients with high residual HK activity, symptoms may not be obvious from childhood into adulthood, and some first experience a hemolytic episode under stressful conditions such as acute infection, pregnancy, or medication use.
In Korea, HNSHA due to HK deficiency is reported very rarely, and the number of cases registered in the national rare disease registry database is extremely small. With the introduction of NGS-based red cell disorder diagnostic panels in Korea, undiagnosed HK deficiency cases are expected to be found in the future. To date, there have been no systematic reports of Korea-specific HK1 pathogenic variants.
HK is the essential first gateway for the entry of glucose into glycolysis. In HK deficiency, because glucose cannot be phosphorylated to G6P, all downstream reactions of glycolysis are blocked, and ultimately ATP production within mature red blood cells is markedly reduced. ATP depletion leads to reduced Na+/K+-ATPase function, reduced membrane deformability, external exposure of phosphatidylserine (PS), and cytoskeletal destabilization, and red blood cells are prematurely destroyed in the reticuloendothelial system, including the spleen (extravascular hemolysis).
The first reaction, in which HK converts glucose to G6P, also supplies G6P, the substrate of the pentose phosphate pathway (PPP). Therefore, in HK deficiency, reduced G6P decreases carbon flow into the PPP, and NADPH production is also partially reduced. This means that red blood cells partially lose their capacity to defend against oxidative stress. However, whether acute hemolytic episodes due to oxidant drugs or fava beans are more prominent in most HK deficiency patients than in PK deficiency has not yet been sufficiently studied.
G6P is also a substrate for glycogen synthesis. Glycogen metabolism is minimal in mature red blood cells, but G6P is linked to various pathways of blood glucose regulation. In HK-deficient red blood cells, glucose consumption itself is reduced, and in some studies apparently higher-than-normal intracellular glucose concentrations have been reported in red blood cells of heterozygous HK deficiency carriers. The clinical significance of these biochemical changes has not been fully elucidated.
The most common time of presentation of HK deficiency is the neonatal period or infancy. Neonatal jaundice is the most common initial symptom, and in severe cases bilirubin may rise to a level requiring phototherapy or exchange transfusion. When severe anemia is present from birth, hydrops fetalis in utero or immediate transfusion after birth may be required. Thereafter, in infancy, persistent pallor, jaundice, and splenomegaly appear, and poor growth may accompany them.
In patients with mild~moderate HK deficiency, chronic fatigue, pallor, exertional dyspnea, and scleral icterus persist beyond childhood. Pigment gallstones are a common complication of chronic hemolysis and can occur even in childhood, sometimes causing cholecystitis or biliary obstruction. As splenomegaly progresses, pancytopenia (hypersplenism) may develop. In transfusion-dependent patients, complications such as endocrine disorders, liver damage, and heart failure due to iron overload may appear in adulthood.
On physical examination of HK deficiency patients, conjunctival pallor, scleral icterus, and skin jaundice appear as signs of chronic anemia and hemolysis. Splenomegaly is a common finding and may be palpable beyond the left costal margin, and in long-standing cases it can become quite large. Right upper quadrant tenderness is observed when there are gallstone complications. When iron overload from repeated transfusions has progressed, findings such as skin pigmentation, hepatomegaly, and growth retardation may be present.
The peripheral blood smear shows a normocytic normochromic anemia pattern, and spherocytes are usually absent or rare. Reticulocytes are markedly increased, reaching several to tens of times normal, reflecting compensatory increased erythropoiesis in response to chronic hemolysis. Elevated serum LDH, elevated indirect bilirubin, and decreased haptoglobin are markers of hemolysis. The direct antiglobulin test (DAT) is negative, and the red cell osmotic fragility test is normal or near normal.
HK deficiency is considered together with PK deficiency in patients with non-spherocytic hemolytic anemia in whom G6PD deficiency, autoimmune hemolytic anemia, and hereditary spherocytosis have all been excluded. In most clinical algorithms, PK enzyme activity is measured first, and after PK deficiency is excluded, measurement of other glycolytic enzyme activities, including HK, follows. Therefore, HK deficiency is often found in the later part of the diagnostic algorithm, after PK deficiency has been excluded.
Red cell HK activity is assessed by quantitative spectrophotometric measurement, but because HK is also abundant in leukocytes, if leukocytes are not completely removed (purified) from the red cell sample, HK activity is often measured as excessively high, resulting in false negatives. For this reason, laboratory diagnosis of HK deficiency is technically more difficult than that of PK deficiency, and reliable results can be obtained only at specialized testing institutions. Adequate removal of leukocytes from blood before testing (LDR, leukodepletion) is an essential pretreatment step for HK measurement.
The key to confirming HK deficiency is quantitative measurement of HK activity in washed red blood cells with adequate leukocyte removal. The test uses glucose and ATP as substrates and measures the rate of NADPH production at 340 nm through a G6PD-coupled reaction. The normal adult HK activity reference is about 1.0~2.5 IU/g Hb, and in HK deficiency patients it is reduced to 50% of this or less. In samples with many reticulocytes, the deficiency may be underestimated because of the high HK activity of young red blood cells, so retesting after separation of aged red blood cells is recommended.
After reduced HK activity is confirmed, or when direct molecular diagnosis is desired, HK1 gene variant analysis is performed. An NGS-based red cell disorder panel (erythrocyte enzymopathy panel) or whole exome sequencing (WES) is efficient. Identified variants are assessed for pathogenicity according to the ACMG/AMP classification criteria, based on databases such as ClinVar and HGMD and on evidence from the literature. Functional studies may be needed, particularly for novel variants.
HK deficiency and PK deficiency have very similar clinical features, and they cannot be differentiated on clinical grounds alone without enzyme activity measurement or molecular analysis. In PK deficiency, 2,3-DPG accumulation is characteristic, so measurement of red cell 2,3-DPG can help in differentiation. In HK deficiency, PEP and 2,3-DPG do not accumulate; rather, all glycolytic intermediates decrease. Red cell metabolite (metabolomics) analysis is useful for confirming the differences in the biochemical profiles of the two diseases.
There is currently no approved specific treatment for HK deficiency, and treatment relies mainly on a conservative approach. Red blood cell transfusion is performed for severe anemia (Hb < 7 g/dL) or marked clinical symptoms. In transfusion-dependent patients, maintaining a regular transfusion schedule and pre-transfusion blood typing and irregular antibody screening are needed. Folic acid intake is recommended to replace folate consumed by chronic hemolysis.
Splenectomy has also been tried in HK deficiency patients, but its effect is reported to be more limited than in PK deficiency. In some patients, transfusion requirements decreased or Hb levels improved after splenectomy, but cases with no effect or only adverse effects have also been reported. Therefore, indications for splenectomy in HK deficiency should be chosen carefully. After splenectomy, vaccination to prevent sepsis caused by encapsulated bacteria is essential.
In severe transfusion-dependent HK deficiency with an HLA-matched donor, allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be considered as curative treatment, and a small number of successful cases have been reported. Preclinical studies (mouse models) of HK1 gene delivery therapy using AAV (adeno-associated virus) vectors are under way, and gene therapy may become a future treatment option. Mitapivat, a treatment for pyruvate kinase deficiency, is not effective in HK deficiency and is not used.
The prognosis of HK deficiency patients varies greatly depending on the degree of residual enzyme activity and the functional impact of the variants carried. In severe homozygous or compound heterozygous patients, transfusion-dependent anemia is established from early after birth, and iron overload from repeated transfusions emerges over time as the main complication. Mild patients can live relatively normal lives, and some can remain transfusion-free into adulthood.
Long-term complications of chronic hemolysis include pigment gallstones, cholecystitis, and pancytopenia due to splenomegaly. Complications of iron overload from repeated transfusions (liver fibrosis, cardiac iron deposition, endocrine abnormalities) may also develop over the course of the disease, and regular monitoring of serum ferritin and organ iron deposition is needed. The very small number of HK deficiency cases means that systematic data on long-term prognosis are lacking, which remains a difficulty for clinical decision-making.
Because HK deficiency is inherited in an autosomal recessive manner, HK activity measurement and HK1 gene variant analysis of parents and siblings are recommended in families in which a patient has been identified. When both parents are carriers, whether a fetus is affected can be determined by prenatal molecular diagnosis in subsequent pregnancies. Given the nature of an ultra-rare disease, the involvement of a rare disease specialty clinic or a clinical genetics specialist is important in genetic counseling.
To prevent acute worsening of hemolysis in HK deficiency patients, vaccination against infections (including parvovirus B19), enhanced monitoring of anemia during pregnancy, and hematologic preparation before surgery are important. Because patients who have undergone splenectomy have a lifelong increased risk of infection by encapsulated bacteria, they should be educated on regular vaccination updates and on immediately visiting a medical institution and receiving antibiotics when they have a fever. For patients diagnosed with HK deficiency, establishing a plan of regular hematologic and biochemical follow-up and maintaining links with a rare disease specialty center are recommended.